아토피피부염에서 ECS 조절을 통한 사백산추출물의 염증 완화 효과
Anti-inflammatory Effect of Sabaek-san Extract through ECS Control in Atopic Dermatitis
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective The purpose of this study was to confirm the effect of Sabaek-san extract on skin damage recovery and inflammation relief in atopic dermatitis-induced mice through Endocannabinoid system (ECS) control. Methods In this study, we used 6-week-old NC/Nga mice were divided into 4 group: control group (Ctrl), lipid barrier elimination group (LBEG), palmitoylethanolamide (PEA) treated group after lipid barrier elimination (PEAG), and Sabaek-san extract treatment group after lipid barrier elimination (SBSG). Each group was assigned 10 animals. After drug administration of three weeks duration following lipid barrier elimination, cannabinoid receptor (CB) 1, CB2, CD (Cluster of Differentiation) 68, phosphorylated inhibitor kappa B (p-IκB), inducible nitric oxide synthase (iNOS), Fc ε receptor, substance P and serotonin were observed to confirm the regulation of the ECS, macrophage activity and mast cell activity. Results We found that 8-hydroxydeoxyguanosine (8-OXdG) positive reaction was significantly lower in the SBST group than in LBET and PEAT groups. Both CB1 and CB2 showed higher positive reactions in the SBST group than in the LBET and PEAT. CD68, p-IκB, iNOS, Fc ε receptor, Substance P and serotonin showed lower positive reaction in the SBST compared to the LBET and PEAT. Conclusion It was confirmed that the Sabaek-san extract can reduce the inflammation of atopic dermatitis by restoring the structural damage of the skin lipid barrier through ECS activity.
Abstract
Objective The purpose of this study was to confirm the effect of Sabaek-san extract on skin damage recovery and inflammation relief in atopic dermatitis-induced mice through Endocannabinoid system (ECS) control. Methods In this study, we used 6-week-old NC/Nga mice were divided into 4 group: control group (Ctrl), lipid barrier elimination group (LBEG), palmitoylethanolamide (PEA) treated group after lipid barrier elimination (PEAG), and Sabaek-san extract treatment group after lipid barrier elimination (SBSG). Each group was assigned 10 animals. After drug administration of three weeks duration following lipid barrier elimination, cannabinoid receptor (CB) 1, CB2, CD (Cluster of Differentiation) 68, phosphorylated inhibitor kappa B (p-IκB), inducible nitric oxide synthase (iNOS), Fc ε receptor, substance P and serotonin were observed to confirm the regulation of the ECS, macrophage activity and mast cell activity. Results We found that 8-hydroxydeoxyguanosine (8-OXdG) positive reaction was significantly lower in the SBST group than in LBET and PEAT groups. Both CB1 and CB2 showed higher positive reactions in the SBST group than in the LBET and PEAT. CD68, p-IκB, iNOS, Fc ε receptor, Substance P and serotonin showed lower positive reaction in the SBST compared to the LBET and PEAT. Conclusion It was confirmed that the Sabaek-san extract can reduce the inflammation of atopic dermatitis by restoring the structural damage of the skin lipid barrier through ECS activity.
참고문헌 (34)
- 김정희, "아토피피부염의 최신지견", Allergy Asthma & Respiratory Disease, 14(1), pp.12~23 (2004), 대한 소아알레르기 호흡기학회
- Leung DY, "Atopic dermatitis", Lancet, 361(9352), pp.151~160 (2003)
- Schneider L, "Atopic dermatitis : a practice parameter update 2012", J Allergy Clin Immunol, 131(2), pp.295~299 (2013)
- Weidinger S, "Atopic dermatitis", Lancet(London, England), 387(10023), pp.1109~1122 (2016)
- Tao Zheng, "The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma", Allergy, Asthma & Immunology Research, 3(2), pp.67~73 (2011), 대한천식알레르기학회
- 지혜미, "2006년 초등학생의 알레르기 질환 유병률의 전국적 역학조사", Allergy Asthma & Respiratory Disease, 19(2), pp.165~172 (2009), 대한 소아알레르기 호흡기학회
- 임광모, "알레르기성 질환에 대한 한의학적 접근", 동의생리병리학회지, 16(5), pp.1~839 (2002), 한의병리학회
- 안강모, "2010년 한국 어린이·청소년의 천식, 알레르기 비결막염, 아토피피부염 증상 유병률 조사: 복합표본설계를 이용한 전국 서베이", 대한의사협회지, 54(7), pp.769~778 (2011), 대한의사협회
- Kim MJ, "A literature study of atopic dermatitis for children", J Pediatr Korean Med, 14(2), pp.167~182 (2000)
- Heo J, "Donguibogam", pp.145~ (1994), Namsandang
- 이동성, "사백산 물 추출물과 30% EtOH 추출물의 항염증 효과 비교연구", 약 학 회 지, 56(4), pp.240~247 (2012), 대한약학회
- 안상현, "사백산 추출물의 지방장벽 생성을 통한 Th2 분화 조절", 대한한방소아과학회지, 36(1), pp.57~64 (2022), 대한한방소아과학회
- 이해자, "瀉白散이 천식유발 백서에서 metrixmetalloproteinase-9(MMP-9)에 미치는 영향", 동의생리병리학회지, 18(6), pp.1694~1698 (2004), 한의병리학회
- Baron ED, "Atopic dermatitis management: comparing the treatment patterns of dermatologists in Japan, U.S.A. and U.K", Br J Dermatol, 147, pp.710~715 (2002)
- Kang MY, "A study on fetal toxicosis removal therapy", J Pediatr Korean Med, 17(1), pp.29~51 (2003)
- 박신형, "HCT116 인체 대장암 세포주에서 상백피 추출물에 의한 전이 억제 효과", 동의생리병리학회지, 35(5), pp.177~184 (2021), 한의병리학회
- Korean Medical Pharmacology Text Publication Committee, "Korean medical pharmacology", pp.116~249 (2010), Shinil Books
- Salzet M, "Invertebrate molecular neuroimmune processes", Brain Res Rev, 34(1), pp.69~79 (2000)
- Miller LK, "The highs and lows of cannabinoid receptor expression in disease : mechanisms and their therapeutic implications", Pharmacol Rev, 63(3), pp.461~470 (2011)
- Pacher P, "The endocannabinoid system as an emerging target of pharmacotherapy", Pharmacol Rev, 58(3), pp.389~462 (2006)
- Kupczyk P, "Cannabinoid system in the skin-a possible target for future therapies in dermatology", Exp Dermatol, 18(8), pp.669~679 (2009)
- Luger TA, "Neuromediators--a crucial component of the skin immune system", J Dermatol Sci, 30(2), pp.87~93 (2002)
- Maccarrone M, "The endocannabinoid system in human keratinocytes : evidence that anandamide inhibits epidermal differentiation through CB1receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase", J Biol Chem, 278(36), pp.33896~33903 (2003)
- Karsak M, "Attenuation of allergic contact dermatitis through the endocannabinoid system", Science, 316(5830), pp.1494~1497 (2007)
- Casanova ML, "Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors", J Clin Invest, 111(1), pp.43~50 (2003)
- Piazza PV, "Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system", Diabetes Metab, 33(2), pp.97~107 (2007)
- Walker JM, "Cannabinoid mechanisms of pain suppression", Handb Exp Pharmacol, 168, pp.509~554 (2005)
- Jhaveri MD, "Endocannabinoid metabolism and uptake : novel targets for neuropathic and inflammatory pain", Br J Pharmacol, 152(5), pp.624~632 (2007)
- Tóth KF, "Cannabinoid signaling in the skin : therapeutic potential of the"c(ut)annabinoid"system", Molecules, 24(5), pp.918~ (2019)
- Arbabi S, "Mitogen-activated protein kinases", Crit Care Med, 30(1), pp.74~79 (2002)
- Chung HY, "Molecular inflammation : underpinnings of aging and age-related diseases", Ageing Res Rev, 8(1), pp.18~30 (2009)
- Baeuerle PA, "NF-kappa B : ten years after", Cell, 87(1), pp.13~20 (1996)
- Aktan F, "iNOS-mediated nitric oxide production and its regulation", Life Sciences, 75(6), pp.639~653 (2004)
- Kay AB, "Allergy and allergic diseases. First of two parts", N Engl J Med, 344(1), pp.30~37 (2001)